CeNeS Pharmaceuticals plc (LSE: CEN), the Cambridge based biopharmaceutical company announced today that Ono Pharmaceutical Co., Ltd. (Osaka, Japan, CEO: Toshiharu Korekane) has obtained from CeNeS the exclusive rights in Japan to develop and commercialize CNS-7056 developed by CeNeS as a general anaesthetic and short-acting sedative. Under this agreement, Ono will pay to CeNeS upfront and milestone payments based on development stage as well as royalties on sales of CNS-7056.
